Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism

Eur J Prev Cardiol. 2020 Nov;27(17):1906-1908. doi: 10.1177/2047487319888596. Epub 2019 Nov 12.

Authors

Augusto Esposito^{1

2}, Emanuele Monda^{1

2}, Felice Gragnano^{1

3}, Fabiana De Simone^{1

2}, Arturo Cesaro^{1

2}, Francesco Natale², Claudia Concilio^{1

2}, Elisabetta Moscarella^{1

2}, Martina Caiazza^{1

2}, Vittorio Pazzanese^{1

2}, Marina Verrengia², Fabio Valente², Daniele Masarone², Francesco Pelliccia⁴, Eduardo Bossone⁵, Paolo Calabro'^{1

3}, Giuseppe Pacileo², Giuseppe Limongelli^{1

2}

Affiliations

¹ Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Italy.
² Cardiomyopathies and Heart Failure Department, Monaldi Hospital, University of Campania 'Luigi Vanvitelli', Italy.
³ Division of Cardiology, A.O.R.N. Sant'Anna e San Sebastiano, Italy.
⁴ Department of Cardiovascular Sciences, Sapienza University, Italy.
⁵ Cardiology Division, A. Cardarelli Hospital, Italy.

PMID: 31718272
DOI: 10.1177/2047487319888596

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Cardiomyopathy, Hypertrophic / etiology*
Female
Humans
Hyperhomocysteinemia / epidemiology
Hyperhomocysteinemia / genetics*
Male
Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
Pilot Projects
Polymorphism, Single Nucleotide
Prevalence
Prognosis
Retrospective Studies

Substances

MTHFR protein, human
Methylenetetrahydrofolate Reductase (NADPH2)